Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation

Karlyn A. Martin*, Jan Beyer-Westendorf, Bruce L. Davidson, Menno V. Huisman, Per Morten Sandset, Stephan Moll

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and prevention in patients with obesity, including phase 3, phase 4, meta-analyses, and pharmacokinetic and pharmacodynamics studies. In addition, we reviewed available data regarding DOACs in bariatric surgery. We provide updated guidance recommendations on using DOACs in patients with obesity for treatment and prevention of VTE, as well as following bariatric surgery.

Original languageEnglish (US)
Pages (from-to)1874-1882
Number of pages9
JournalJournal of Thrombosis and Haemostasis
Volume19
Issue number8
DOIs
StatePublished - Aug 2021

Keywords

  • anticoagulant
  • bariatric surgery
  • direct oral anticoagulant
  • obesity
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation'. Together they form a unique fingerprint.

Cite this